天美传媒

Barbara Burtness, MD is a Professor of Medicine (Medical Oncology) at the Yale School of Medicine, Chief Translational Research Officer, and Associate Cancer Center Director for Translational Research at the Yale Cancer Center. She serves as Co-Leader of the Developmental Therapeutics Program, Division Chief for Head and Neck/Sarcoma Oncology, and Director of the Yale Head and Neck Specialized Program of Research Excellence. Dr. Burtness is internationally recognized for her research in head and neck cancer. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee and the ECOG-ACRIN Task Force for the Advanc, and leads national and international trials of targeted therapy in head and neck cancer. Her laboratory studies synthetic lethal therapeutic strategies in head and neck cancer and the targeting of aurora kinase A to overcome adaptive resistance to EGFR inhibition and - in lung cancer- to direct KRAS inhibition. 

Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma 鈥� a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.
Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.
鈥淪killed and experienced radiologists are rare for this relatively new technique,鈥� Dr. Sprenkle explains. 鈥淎t Yale, we are fortunate to have some of the world leaders in prostate MRI.鈥�
Dr. Sprenkle is also a pioneer in 鈥渇ocal therapy,鈥� which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects鈥攕uch as erectile dysfunction and incontinence鈥攖hat may follow the removal of the whole prostate.
鈥淓xciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,鈥� Dr. Sprenkle says. 鈥淒eveloping ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.鈥�
Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. 鈥淚 want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.鈥�

Education & Training:
Non Degree Program-Yale School of Management, Emerging Leaders Program (2018)
Fellowship-Memorial Sloan Kettering Cancer Center (2011)
Residency-New York Presbyterian Hospital (2009)
Internship-New York Presbyterian Hospital (2005)
MD-Columbia University (2004)
BA-Stanford University, Human Biology (1998)

Dr. Shulman studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas.




 

Jonathan C. Trent, MD, PhD, is professor of medicine, associate director for clinical research, and director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL. He earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center and a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller, he held appointments as faculty of The University of Texas Graduate School of Biomedical Sciences at Houston and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.